Biotech Values

[tinkershaw]

Dew, that is a literal and open tacit invitation for MNTA to submit their application so that the FDA can have one example to work with to demonstrate this two track path they are talking about.

Directly substitutable vs. branded similars? I don't see how branded similar compete vs. a directly substitutable bioidentical.

What is the process here, will there be direct substitutability or will MNTA and its partner need to market it like a branded?

This screams, "MNTA, we need some regulations and templates, show us how it is done so we can do our job."

Further reduces the risk and increases the reward for MNTA.

Tinker